Skip to NavigationSkip to content

Roche's first-line Tecentriq combo scores accelerated FDA review

Published on 05/12/18 at 12:01pm

Roche’s immunotherapy Tecentriq has secured Priority Review from the FDA, the company has announced, in combination with carboplatin and etoposide (chemotherapy) for the first-line treatment of extensive-stage small cell lung cancer (ESCLC).

The fast-tracked review was obtained on the back of data which showed that the Tecentriq combo provided benefit in overall survival (OS) and progression-free survival (PFS) in ESCLC, and means that a final verdict on whether to approve the therapy in the US is expected to be made by 18 March 2019.

The combo has already gained approval from the FDA in metastatic non-small cell lung cancer (NSCLC) in patients whose disease has progressed during or following platinum-based chemotherapy, or have seen progression from an FDA-approved targeted therapy if their tumour has ALK or EGFR gene abnormalities.

“It’s been more than 20 years since there has been a new initial treatment option for extensive-stage small cell lung cancer that delivers a clinically meaningful survival benefit,” said Dr Sandra Horning, Chief Medical Officer and Head of Global Product Development. “We are working closely with the FDA to bring this Tecentriq-based regimen to people with this difficult-to-treat type of lung cancer as soon as possible.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches